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REGULAR ARTICLE
ESRRB regulates glucocorticoid gene expression in mice and patients with
acute lymphoblastic leukemia
Kayleigh M. Gallagher,1 Justine E. Roderick,1 Shi Hao Tan,2 Tze King Tan,2 Leonard Murphy,1 Jun Yu,1 Rui Li,1 Kevin W. O’Connor,1
Julie Zhu,1 Michael R. Green,1 Takaomi Sanda,2 and Michelle A. Kelliher1
1Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA; and 2Cancer Science Institute of Singapore, Center of
Translational Medicine, Singapore
Key Points
• Repression of ESRRB
results in glucocorti-





• ESRRB agonists syn-
ergize with dexametha-
sone to induce human
leukemic cell death.
Synthetic glucocorticoids (GCs), such as dexamethasone and prednisone, remain key
components of therapy for patients with lymphoid malignancies. For pediatric patients with
acute lymphoblastic leukemia (ALL), response to GCs remains the most reliable prognostic
indicator; failure to respond to GC correlates with poor event-free survival. To uncover GC
resistance mechanisms, we performed a genome-wide, survival-based short hairpin RNA
screen and identified the orphan nuclear receptor estrogen-related receptor-b (ESRRB) as
a critical transcription factor that cooperates with the GC receptor (GR) to mediate the GC
gene expression signature in mouse and human ALL cells. Esrrb knockdown interfered with
the expression of genes that were induced and repressed by GR and resulted in GC resistance
in vitro and in vivo. Dexamethasone treatment stimulated ESRRB binding to estrogen-
related receptor elements (ERREs) in canonical GC-regulated genes, and H3K27Ac
Hi-chromatin immunoprecipitation revealed increased interactions between GR- and
ERRE-containing regulatory regions in dexamethasone-treated human T-ALL cells.
Furthermore, ESRRB agonists enhanced GC target gene expression and synergized with
dexamethasone to induce leukemic cell death, indicating that ESRRB agonists may
overcome GC resistance in ALL, and potentially, in other lymphoid malignancies.
Introduction
Glucocorticoids (GCs) are critical components of multiagent chemotherapy for lymphoid malignancies.
Of the lymphoid malignancies, acute lymphoblastic leukemia (ALL) is the most common one that occurs
in childhood and involves transformation of B- or T-lymphoid progenitors.1,2 A patient’s response to GCs
is the most reliable prognostic indicator in pediatric ALL, and GC resistance remains an obstacle to
improving the outcomes of these patients.3,4 In lymphoid cells, synthetic GCs such as dexamethasone
induce apoptosis by stimulating GC-receptor (GR) translocation to regulate transcription.5 In lymphoid
cells, GC treatment induces proapoptotic genes, including BCL2L11 (BIM). There is also evidence that
the GR represses expression of the prosurvival genes BCL2 and BCL-XL.6
GC resistance can result from mutation in NR3C1, which encodes the GR; however, these mutations are
rare in patients with relapsed ALL.7 GR activity can also be impaired by AKT-mediated phosphorylation of
the GR or by NLRP3 inflammasome activation and caspase 1-mediated cleavage of the GR.8,9 Impaired
GC responses can also result from missense mutations in NR3C1 coactivators such as CREBBP.10
Several mechanisms of GC resistance involve activation of prosurvival pathways, including LCK, FLT3,
WNT, MAPK, IL-7-JAK/STAT, and mTOR signaling.11-17 An impaired GC response in ALL can also
reflect increased DNA methylation of the BCL2L11 locus observed in a subset of GC-resistant
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patients.18 Last, mutations in NOTCH1 increase HES1 levels, which
interfere with GR autoregulation, contributing to GC resistance.19
To further elucidate GC resistance mechanisms in ALL, we performed
a short hairpin RNA (shRNA) screen in primary T-ALL cells isolated
from a Tal1/Lmo2 mouse T-ALL model.20 We found that shRNAs
targeting the GR (Nr3c1) or known GC resistance genes (Rcan1,
Mllt10, Smarca1, Smard2, and Btg1) were enriched in the
screening. Importantly, shRNAs for Ikzf1, Utx, and the CREBBP
paralogue Ep300, known leukemia-suppressor genes in human
ALL, conferred dexamethasone resistance in our mouse screening.
An shRNA targeting the estrogen related receptor-b (ESRRB) was
identified in the screening. ESRRB is a member of the estrogen-
related receptor (ERR) family of orphan nuclear receptors and is
known to act as a constitutively active transcription factor that
binds an estrogen-related response element (ERRE) to regulate
gene expression.21 ESRRB has been studied in mouse embryonic
stem (ES) cells, where ESRRB maintains self-renewal through
activation of Oct-4 and as a member of the NANOG complex.22,23
We revealed novel functions of ESRRB in the control of GR-mediated
transcription and showed that an ESRRB agonist potentiates
dexamethasone-induced gene expression and apoptosis. The
data suggest that ESRRB agonists may provide therapeutic
benefit to GC-resistant patients with ALL.
Materials and methods
Mice and cells
Tal1/Lmo2 transgenic mice, generated when M.A.K. was a postdoc
at Harvard Medical School, were monitored for leukemia, and
mouse and human T-ALL cells were cultured as described.24
Primary human T-ALL samples were expanded in NSG mice and
cultured as previously described.25 All animal procedures used
in this study were approved by the University of Massachusetts
Medical School Institutional Animal Care and Use Committee.
Cell proliferation and death assays
Mouse or human ALL cell lines or samples were cultured in increasing
concentrations of dexamethasone (0-10 mM) for 24 to 72 hours,
and cell viability was monitored by trypan blue staining and cell
proliferation was observed by carboxyfluorescein succinimidyl
ester (CFSE) staining followed by flow cytometry. Metabolic
activity was also assayed by using CellTiter-Glo chemilumines-
cence reagent (Promega). Mouse and human leukemic cells were
treated with dexamethasone, 2 3 105 cells were stained with
annexin V-fluorescein isothiocyanate and 7-aminoactinomycin D
(7-AAD), and apoptotic cells were quantified by flow cytometry. The
synergistic relationship between dexamethasone and ESRRB
agonists was determined by the Chou-Talalay method.26
Quantitative real-time polymerase chain reaction
Total RNA was extracted by using Trizol, and cDNA was synthesized
from RNA (2 mg) by using the Superscript First-Strand Synthesis
System (Invitrogen). Quantitative real-time- polymerase chain
reaction (qRT-PCR) was performed on the AB7300 Detection
System (Applied Biosystems), using Power SYBR Green Master
Mix (Applied Biosystems) and gene-specific primers. Gene
expression was determined using the DD cycle threshold (DDCT)
method and normalized to b-actin. Specific primer sequences
are provided in supplemental Table 5.
RNA sequencing and
chromatin immunoprecipitation-qPCR
RNA was isolated from mouse T-ALL cells infected with non-
silencing (NS) Nr3c1 or Esrrb shRNAs treated with vehicle or
dexamethasone for 6 hours, using the Invitrogen RNA mini kit.
RNA was sent to BGI (Shenzhen, China) for library preparation
and paired-end sequencing. RSEM was used to quantify RNA-
sequencing results.27 For chromatin immunoprecipitation (ChIP),
107 human ALL cells (KOPTK1) were treated with dexamethasone
or dimethyl sulfoxide (DMSO) for 12 hours, and ChIP-qPCR was
performed as previously described.28 Specific primer sequences
are in supplemental Table 5.
Hi-ChIP
T-ALL cells (1 3 107) were cross-linked for 10 minutes in 1%
formaldehyde solution. Nuclei were harvested and sonicated on
a Covaris ME220 for 6 minutes. Chromatin was incubated with
7.5 mg of H3K27ac antibody overnight at 4°C. The next day, 60 mL
of protein G magnetic beads was used to isolate antibody-bound
chromatin. DNA was then purified with DNA Clean and Concen-
trate 5 columns (D4013; Zymo), and PCR amplification was
performed. DNA was purified and sequenced by BGISeq500, using
a 50-bp paired-end library. Full Hi-ChIP method is available in the
supplemental Methods and has been adapted from the original
publication.29
Results
The orphan nuclear receptor ESRRB regulates
GC-induced cell death in vitro and in vivo
To identify GC resistance genes, we transduced the dexamethasone-
sensitive mouse T-ALL cell line 1390 with a whole-genome lentiviral
TRC (The RNAi Consortium) library containing ;75000 shRNA
constructs directed against 16 000 genes. Leukemic cells were
infected with a multiplicity of infection of 0.2 to achieve a single
shRNA per cell. Infected cells were selected with puromycin for
48 hours and treated with dexamethasone for 4 days to kill .99%
of the leukemic cells. Surviving cells were expanded and sequenced
to identify shRNAs that confer dexamethasone resistance (Figure 1A).
This screen identified an shRNA specific for ESRRB, an orphan
nuclear receptor containing a zinc-finger DNA binding domain and
a ligand binding domain that contains an activation function (AF)-2
domain for the recruitment of coactivators or corepressors (Figure 1B).
We achieved .50% knockdown of Esrrb in mouse T-ALL cells,
using 2 independent shRNAs (Figure 1C; supplemental Figure 1A).
To determine whether ESRRB alters dexamethasone response, we
treated leukemic cells deficient for Esrrb or Nr3c1 encoding the GR
with dexamethasone and assessed cell viability by MTS assay and
cell death by annexin V/7-AAD staining. Knockdown of Esrrb
prevents dexamethasone-induced cell death and shifts the GI50
for dexamethasone ;96-fold from 6 to 564 nM, or 17-fold when
a second, less effective, Esrrb shRNA is used (Figure 1D-E). We
examined GC responses in an additional mouse T-ALL cell line
(5059) and found that Esrrb knockdown shifted the GI50 from 8
to 70 nM and prevented dexamethasone-induced apoptosis
(Figure 1F-G). Although we showed that an ESRRB-deficiency
results in dexamethasone resistance in vitro, we recognized that
dexamethasone resistance in vivo may be influenced by prosurvival
factors. For example, the lymphoid survival factor IL-7 can contribute
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to dexamethasone resistance.11 Therefore, we examined the effects
of Esrrb knockdown on the dexamethasone response in vivo.
Mouse T-ALL cells deficient for Esrrb or Nr3c1 were transplanted
into sublethally irradiated syngeneic recipients, and the mice were
treated with vehicle or dexamethasone (15 mg/kg) for 3 weeks
(Figure 1H). In mice receiving transplants of leukemic cells
expressing an NS control, dexamethasone significantly prolonged
survival and eliminated disease in 4 of 10 mice (Figure 1I). In
contrast, dexamethasone treatment had no significant effect on the
survival of mice that received Esrrb- or Nr3c1-deficient leukemic
cells; all animals succumbed to the disease (Figure 1J-K). These
data demonstrate that an ESRRB-deficiency results in GC
resistance in vivo.
ESRRB has no effect on the leukemic gene expression
signature or on leukemic growth
ESRRB is required for embryonic stem (ES) cell pluripotency
and self-renewal of trophoblast stem cells.30 Moreover, ESRRB
functions as a mitotic bookmarking factor in ES cells.31 These
findings suggest that ESRRB may alter leukemic cell pro-
liferation. We examined ESRRB effects on leukemic growth by
labeling mouse leukemic cells expressing an NS control or Esrrb-
specific shRNAs with CFSE and monitored proliferation. An
ESRRB-deficiency had no significant effect on CFSE loss or
dilution, because of proliferation. Furthermore, a similar number
of leukemic cells was observed in cultures expressing NS- or
Esrrb-specific shRNAs (supplemental Figure 1B-C). To examine
the effects of an ESRRB-deficiency on leukemic gene expression,
we performed RNA sequencing on NS- and Esrrb-knockdown
cells and found that Esrrb knockdown had no effect on basal
leukemic gene expression (supplemental Figure 1D). To assess
the effects of ESRRB on leukemic growth in vivo, we transplanted
mouse leukemic cells expressing NS or Esrrb-specific shRNAs
into sublethally irradiated, syngeneic mice and monitored disease
progression. Consistent with the gene expression studies, an
ESRRB deficiency had no significant effects on leukemic growth
in vivo (supplemental Figure 1E; P 5 .4).
ESRRB cooperates with GR to potentiate
dexamethasone-induced gene expression
GCs, such as dexamethasone, induce cell death in lymphoid cells
by activating GR-mediated transcription.5 We hypothesized that
ESRRB deficiency would mediate GC resistance by interfering
with expression of GR-regulated genes. We performed RNA
sequencing on vehicle or dexamethasone-treated mouse leukemic
cells expressing NS control or Nr3c1- or Esrrb-specific shRNAs.
Our RNA-sequencing studies revealed 339 genes of diverse
functions that were altered by dexamethasone treatment of T-ALL
cells and, as expected, gene expression was significantly
abrogated by Nr3c1 knockdown (Figure 2A-B; supplemental
Figure 2). Surprisingly, we found that dexamethasone-regulated
gene expression was also abrogated by Esrrb knockdown, with
66% of dexamethasone-induced genes dependent on ESRRB
(Figure 2A). Gene set enrichment analysis revealed that
dexamethasone-regulated gene expression correlated negatively
with Esrrb or Nr3c1 knockdown when compared to leukemic cells
expressing the NS control (Figure 2B, top). Analysis of the log-fold
change in NS or Esrrb- or Nr3c1-silenced leukemic cells showed
that the greatest induction of dexamethasone-regulated genes
occurred in the NS control leukemic cells, and Esrrb knockdown
reduced the expression of 143 of the 214 dexamethasone-
induced genes (66%; Figure 2B, bottom). These data reveal that,
similar to NR3C1-deficiency, Esrrb knockdown interfered with
dexamethasone-induced gene expression in mouse T-ALL cells.
To identify the biological processes regulated by the GR and
ESRRB, we performed gene ontology analysis using DAVID32,33
and found genes enriched for cell death. In fact, dexamethasone
induced expression of 42 genes related to cell death, 26 of which
were dependent on ESRRB (supplemental Table 1). The ESRRB-
dependent proapoptotic genes include Tsc22d3, which encodes
GC-induced leucine zipper, known to trigger thymocyte apoptosis
when overexpressed,34 and the proapoptotic Bcl2l11 gene, which
encodes BIM (supplemental Table 1). Although Bcl2l11 scored just
below the 1.5-fold cutoff, qRT-PCR with 2 independent shRNAs
confirmed that Bcl2l11, Tsc22d3, and Nr3c1 expression signifi-
cantly decreased in dexamethasone-treated Esrrb-knockdown
leukemic cell lines (Figure 2C). Additional ESRRB-dependent
genes include the death-associated protein kinase Stk17b, the
Litaf gene implicated in B-cell apoptosis, and the p53 targets
Epha2 and Acer2.35-38 Induction of proapoptotic BIM is critical for
dexamethasone-induced cell death, and we confirmed that Esrrb
knockdown reduces BIM protein levels by approximately twofold.18,39
Importantly, we saw induction of the short BIM isoform, the most
potent inducer of apoptosis, reduced by more than threefold
(Figure 2D).40 These data suggest that the dexamethasone
resistance observed in ESRRB-deficient leukemic cells can be
explained in part by a failure to induce proapoptotic genes and
sufficient BIM protein levels.
Figure 1. The orphan nuclear receptor ESRRB regulates GC-induced cell death in vitro and in vivo. (A) ESRRB was identified as a mediator of GC resistance in
a whole-genome mouse shRNA screen, using the whole-genome TRC shRNA library. (B) ESRRB contains a ligand and DNA binding domain that binds an ERRE site and
mediates transcriptional changes via the recruitment of coactivator or corepressor proteins to its AF2 domain. (C) Mouse T-ALL cells (1390) were transduced with lentiviruses
expressing NS control or 2 independent shRNAs targeting mouse Esrrb (1, 2) or Nr3c1 and Esrrb and Nr3c1 mRNA expression was analyzed by qRT-PCR. The copy number
was normalized to b-actin using the DDCT method. Knockdown of Esrrb in mouse T-ALL cells 1 (1390) and 2 (5059) resulted in resistance to dexamethasone-induced
apoptosis. (D,F) Mouse T-ALL cells expressing NS or Esrrb-shRNAs were cultured with dexamethasone (50 nM) for 2 days, and apoptosis was assayed by annexin V-FITC/7-
AAD staining followed by flow cytometry. (E,G) ESRRB repression significantly shifted dexamethasone GI50. NS cells or cells deficient in ESRRB or NR3C1 were cultured in
increasing concentrations of dexamethasone for 48 hours, and viability was assayed by MTS. Absorbance values were normalized to vehicle control. (H) Experimental approach
to examine dexamethasone response in vivo. Esrrb or Nr3c1 knockdown mediated dexamethasone resistance in vivo. Kaplan-Meier survival curves demonstrate that dexametha-
sone significantly delayed disease in mice receiving transplants of mouse T-ALL cells transduced with NS shRNA (I) but had no effect on mice receiving transplants of
Nr3c1- (J) or Esrrb- (K) gene–specific shRNAs (n 5 5-7 mice per group; statistics by log-rank test). The results are averages of 3 independent experiments; error bars
represent standard error of the mean (SEM). *P , .05; **P , .01; ***P , .001. NS, not significant.
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Figure 2. ESRRB cooperates with GR to potentiate
dexamethasone-induced gene expression. RNA was
isolated from mouse T-ALL cells infected with NS, Nr3c1, or
Esrrb shRNAs treated with vehicle (DMSO) or dexametha-
sone (100 nM) for 6 hours and sequenced using BGI-seq
500. RSEM was used to quantify RNA-sequencing results.
(A) The heat map represents differentially expressed genes
between vehicle- and dexamethasone-treated NS cells using
log 1.5-fold cutoff (n 5 3 replicates). (B) Gene set enrich-
ment analysis (top) on dexamethasone-induced gene set
shows significant negative correlation in Esrrb-knockdown
leukemic cells treated with dexamethasone (P , .001). Distri-
bution of log fold change across detected genes (bottom).
The NS cells exhibit the highest average log fold change
when treated with dexamethasone, whereas Nr3c1 or Esrrb
knockdown interferes with optimal changes in gene expres-
sion. Nr3c1, Bcl2l11, and Tsc22d3 are GR-regulated genes
dependent on ESRRB for their expression. (C) Control or
Esrrb-knockdown cells (2 independent shRNAs) were treated
with dexamethasone for 6 hours, and Nr3c1, Bcl2l11, and
Tsc22d3 mRNA expression was analyzed by qRT-PCR. The
copy number was normalized to b-actin using the DDCT
method. (D) BIM protein expression was analyzed by immu-
noblot after 12 hours of dexamethasone (100 nM) treatment
in NS or Nr3c1- or Esrrb-knockdown cells. Protein was quan-
tified using densitometry and normalized to actin. The results
are averages of 3 independent experiments; error bars repre-
sent SEM. **P , .01; ***P , .001.











SETTS user on 10 August 2020
Our RNA-sequencing data also revealed a set of GC-repressed
genes that were influenced by ESRRB. Approximately 58% of the
dexamethasone-repressed genes were affected by Nr3c1 knock-
down and 54% of these repressed genes appeared to be ESRRB
dependent (supplemental Figure 3A-B). Consistent with anti-
inflammatory functions of the GR, we found that the repressed
genes were related to immune regulation (supplemental Table 2).
Interestingly, we found that genes important in thymocyte differen-
tiation, includingMyb, Rag1, Rasgrp1, and Runx1, are repressed by
dexamethasone in an ESRRB-dependent manner. These data are
consistent with published B-ALL studies, which implicate GC
repression of B-cell development genes in the therapeutic re-
sponse.41 We validated the repressive effects of ESRRB on 3
randomly selected candidate genes, Bcl2l1, Rag1, and Klf3, in
mouse leukemic cells by qRT-PCR and found expression of these
genes to be unaffected by dexamethasone in ESRRB-knockdown
cells (supplemental Figure 3C). This finding is consistent with
studies in human ALL cells, where dexamethasone repressed BCL2
and BCL2L1.6 Because Bcl2l1 (encoding BCL-XL) expression was
not significantly repressed in ESRRB-knockdown cells, we used the
ABT-263 inhibitor of BCL-XL and found that ABT-263 treatment
resensitized ESRRB-deficient cells to dexamethasone-induced apo-
ptosis (supplemental Figure 3D). Collectively, these data reveal that
ESRRB cooperates with the GR to regulate gene expression and is
consistent with known functions, where ESRRB recruits coactivators
and corepressors to regulate gene expression.21
GBS- and ERRE-containing cis-regulatory elements
interact with promoter regions of GR- and
ESRRB-dependent genes in mouse T-ALL cells
Our RNA-sequencing data revealed that most dexamethasone-
regulated genes in mouse T-ALL cells depend on ESRRB. We
examined the GR- and ESRRB-dependent genes for the
presence of ERREs. Motif analysis revealed ERREs in 49% of
these genes, with 18% of the genes harboring ERREs in
promoters, 31% in putative enhancer regions, and 6% in both
promoters and enhancers (Figure 3A). We then performed
H3K27Ac Hi-ChIP in the mouse T-ALL cell line (2553) and
detected preestablished interactions between putative enhancer
regions and looping between promoter-enhancer elements in the
GR/ESRRB-dependent genes examined (Figure 3B). Using published
GR ChIP-sequencing data42 we confirmed GR binding to the pro-
moter and/or enhancer regions of Tsc22d3, Camk1d, and Sh3rf1
(Figure 3B; arrows). We then validated these findings in 2 additional
mouse T-ALL cell lines (720 and 1390; supplemental Figure 4).
ESRRB regulates gene expression in ESCs through complex
formation with NANOG,23 suggesting that an ESRRB/GR complex
may regulate GC gene expression. Co-IP experiments, however,
failed to detect an ESRRB/GR complex in ALL cells or in
transfected HEK293T cells (supplemental Figure 5A-B). Our
analysis of the GR/ESRRB-dependent genes in mouse T-ALL cells
found GR and ERRE motifs to be nonoverlapping (Figure 3A),
leading us to hypothesize that ESRRB and GR bind DNA
independently; however, 36% of genes harbored sites that were
separated by.10 kb, suggesting that ESRRB and GR may interact
to mediate chromatin looping.
We next examined the effects of dexamethasone on H3K27Ac
levels and chromatin looping in human T-ALL cells, by using the
canonical GR target genes PIK3IP1, FKBP5, and TSC22D3
identified by Piovan et al.8 Similar to our Hi-ChIP studies in mouse
T-ALL cells (Figure 3), we detected preexisting promoter/enhancer
interactions in PIK3IP1, TSC22D3, andBCL2L11 (Figure 4A,C-D).
We used virtual 4C analysis of our Hi-ChIP data to quantify
interaction frequency. Using the transcription start site of these
GR-regulated genes as the viewpoint (red highlight), we find that
dexamethasone significantly increased the frequency of promoter
interactions with GR-bound and ERRE-containing enhancer
elements; furthermore, dexamethasone increased H3K27Ac levels
at these putative enhancers (Figure 4A-C). Similarly, we detected
increases in active histone marks and promoter/enhancer inter-
actions at the BCL2L11 locus, where our Hi-ChIP data validated
the presence of a dexamethasone-responsive intronic enhancer
(Figure 4D), previously observed in GC-sensitive ALL cells.39
Together, these data suggest that GR and ESRRB binding support
these promoter/enhancer interactions to potentiate gene expres-
sion (Figure 4E).
Knockdown of ESRRB prevents
dexamethasone-induced cell death and gene
expression in human ALL cells
We then generated ESRRB-deficient human T- and B-ALL cells
and assayed the dexamethasone response. We validated ESRRB
knockdown by qRT-PCR and by immunoblot analysis (supplemental
Figure 5C-E). Similar to our findings in mouse T-ALL cells, ESRRB
knockdown in the human T-ALL cell line DND41 shifted the
dexamethasone GI50 from 79 to 840 nM or 410 nMwhen a second
shRNA was used (Figure 5A). As with NR3C1 knockdown, both
ESRRB shRNAs prevented dexamethasone-induced apoptosis of
human T-ALL cells and interfered with dexamethasone-induction of
the GR target genes NR3C1, BCL2L11, and TSC22D3 (Figure
5B-C). ESRRB knockdown in the human T-ALL cell line KOPTK1
also prevented dexamethasone-induced gene expression and
apoptosis (supplemental Figure 5F-G). Similarly, a deficiency in
ESRRB in NALM-6 cells shifted the dexamethasone GI50 from 56
to 870 nM or 876 nM when a second independent ESRRB shRNA
was used (Figure 5D; supplemental Figure 5D). ESRRB knock-
down significantly reduced the percentage of apoptotic leukemic
cells and interfered with dexamethasone-induced gene expression
in NALM-6 cells (Figure 5E-F). These data suggest that ESRRB
contributes to GC resistance in human T- and B-ALL and indicate
that, although performed in mouse T-ALL cells, the genes identified
in our screening may be relevant to steroid resistance in other
lymphoid malignancies.
Dexamethasone increases ESRRB expression and
binding to GR-regulated genes
The effects of ESRRB repression on dexamethasone-induced gene
expression suggests that ESRRB cooperates with the GR to induce
optimal transcriptional responses to dexamethasone. Therefore, we
hypothesized that dexamethasone may induce ESRRB expression
to amplify the GC response. We treated human T-ALL cells with
dexamethasone for 6 hours and detected significant increases in
ESRRB protein levels (Figure 6A). We analyzed the genomic
sequence of canonical GC-regulated genes including NR3C1,
BCL2L11, and TSC22D3 and found an ERRE (TCAAGGTCA) in
intronic regions of all 3 genes. We performed ChIP-qPCR in the
human T-ALL cell line KOPTK1 and assayed ESRRB binding to













































chrX: 140,510,000 140,520,000 140,530,000 140,540,000 140,550,000 140,560,000
mm1020 kb
5,350,000 5,400,000 5,450,000 5,500,000 5,550,000 5,600,000 5,650,000 5,700,000 5,750,000
mm10200 kb
Figure 3. GBS- and ERRE-containing cis-regulatory elements interact with promoter regions of ESRRB- and GR-regulated genes in mouse T-ALL cells. (A)
Distribution of ERREs in GR-regulated, ESRRB-dependent genes. (B) H3K27Ac Hi-ChIP tracks of 3 ESRRB/GR-dependent mouse genes show preexisting promoter inter-
actions with active ERRE-containing enhancers known to bind the GR. Black lines indicate the anchors of interaction.











SETTS user on 10 August 2020
these regions. We detect increased ESRRB binding to 3 ERRE
sites in intron 1 of the NR3C1 gene after dexamethasone
treatment (Figure 6B). These data are consistent with our gene
expression data and qRT-PCR analyses showing that ESRRB is
required for GR autoinduction (Figures 2C and 5C,F). ESRRB
recruitment to the ERRE in intron 2 of BCL2L11 and a TSC22D3
enhancer was also observed in human T-ALL cells treated with
dexamethasone (Figure 6C-D). The direct binding of ESRRB to
dexamethasone-regulated genes in human T-ALL cells further
implicated ESRRB in GR-mediated transcription. Interestingly,
we detected significant ESRRB recruitment to BCL2L11 and
TSC22D3 in the GC-sensitive human T-ALL cell line KOPTK1,
whereas significantly less ESRRB recruitment to these genes
was observed in the GC-resistant human T-ALL cell line CUTLL1,
which also does not upregulate ESRRB expression in response to

































































































Figure 4. Dexamethasone increases H3K27Ac levels
and promoter/enhancer interactions in canonical GC-
regulated genes in human T-ALL cells. H3K27Ac Hi-
ChIP tracks (top) showing interaction between H3K27Ac
regions in canonical GC target genes PIK3IP1 (A), FKBP5
(B), TSC22D3 (C), and BCL2L11 (D), treated with DMSO
(pink track) or dexamethasone (blue track). Black lines in-
dicate the anchors of interaction. Virtual 4C extract from
Hi-ChIP (bottom) shows interaction frequency from the view-
point (red highlight) of GC target genes PIK3IP1 (A), FKBP5
(B), TSC22D3 (C), and BCL2L11 (D), treated with DMSO
(yellow) or dexamethasone (blue). ESRRB binding sites were
determined using the ERRE consensus site AAGGTCA. GR
binding sites were determined using published ChIP se-
quencing data in T-ALL patient samples.39 (E) Hi-ChIP data
for BCL2L11 was used to model ESRRB regulation of GC-
induced gene expression. Dexamethasone triggered GR and
ESRRB and coactivator binding to the BCL2L11 enhancer
(red) which looped back to the promoter (green) to recruit
RNA polymerase II and the transcription initiation complex,
thereby inducing BCL2L11 expression.

































































































































































































































































































































































Figure 5. ESRRB regulates dexamethasone-induced gene expression and cell death in human ALL cell lines. (A,D) The human T-ALL cell line DND-41 and the
human pre-B-ALL cell line NALM-6, transduced with lentiviruses expressing NS control or shRNAs targeting ESRRB or NR3C1, were cultured in increasing concentrations of
dexamethasone for 72 hours, and viability was assayed by MTS. Absorbance values were normalized to vehicle control. (B,E) ESRRB knockdown in human T-ALL cells
conferred resistance to dexamethasone-induced apoptosis. Silenced cells were cultured with dexamethasone for 2 days, and apoptosis was assayed by annexin V-FITC/7-AAD
staining followed by flow cytometry. (C,F) Optimal dexamethasone-induced NR3C1, BCL2L11, and TSC22D3 gene expression required NR3C1 and ESRRB. Control or
knockdown cells were treated with dexamethasone for 24 hours, and NR3C1, BCL2L11, and TSC22D3 mRNA expression was analyzed by qRT-PCR. The copy number was
normalized to b-actin by the DDCT method. The results are averages of 3 independent experiments; error bars represent SEM. *P , .05; **P , .01; ***P , .001.
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we did not detect increased ESRRB binding to regions of
BCL2L11 or TSC22D3 that did not contain an ERRE or exhibit
GR binding (supplemental Figure 6B-C). 39 These findings are
consistent with recent ATAC-seq studies that show increased
chromatin accessibility in GC-regulated genes in GC-sensitive
vs GC-resistant ALL cells.18 Taken together, these data demonstrate
that in addition to changes in H3K27 acetylation and promoter-
enhancer interactions (Figure 4), dexamethasone increased ESRRB
binding to the ERRE in GC-sensitive ALL cells and suggest direct





































































































































































































Figure 6. Dexamethasone increases ESRRB expression and binding to GR-regulated genes. (A) The human T-ALL cell lines DND-41 and KOPTK1 were treated with
dexamethasone for 6 hours, and ESRRB expression was quantified in nuclear lysates by immunoblot analysis with an ESRRB antibody. ESRRB protein levels were quantified
by densitometry. ESRRB bound GC target genes in dexamethasone-sensitive (KOPTK1) but not dexamethasone-resistant (CUTLL1) human T-ALL cells. (B-D) The schematics
(top) show putative ERRE sites in introns of GR target genes. ChIP (bottom) was performed with an ESRRB antibody or an IgG control, and DNA was quantified by qPCR and
the DDCT method, with primers to the putative ESRRB binding sites. The percentage input was normalized to IgG control. The results are averages of 3 independent experi-
ments; error bars represent SEM. *P , .05; **P , .01.









































































































































































































































































































































































































































Figure 7. The ESRRB agonist GSK4716 synergizes with dexamethasone to induce human leukemic cell death. (A) Dexamethasone and DY131 dual treatment
increase GC-induced apoptosis in human ALL cells in vitro. Human ALL cell lines were treated with vehicle (DMSO), dexamethasone (1 mM), DY131 (10 mM), or
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The ESRRB agonist GSK4716 synergizes with
dexamethasone to induce human leukemic cell death
The role of ESRRB in the regulation of GR target genes suggests
that ESRRB expression is reduced in samples from relapsed ALL.
We compared ESRRB expression in paired ALL samples obtained
at diagnosis and upon relapse.43 We found ESRRB expression
significantly reduced in 24 of 49 ALL samples at the time of relapse
(supplemental Figure 7A; P , .05) further implicating ESRRB in
dexamethasone resistance. We did not, however, detect evidence
of ESRRB promoter methylation in samples from relapsed patients
(supplemental Figure 7B). We also analyzed ESRRB expression in
GC-sensitive and -resistant samples from patients with ALL and
found ESRRB significantly reduced in GC-resistant samples in 1 of
2 data sets examined (supplemental Figure 7C-D).9,39 We
examined additional ALL data sets to determine whether ESRRB
levels correlate with genetic subtypes of ALL. Although no
significant differences were detected among B-ALL subtypes
(supplemental Figure 7E), ESRRB expression was significantly
reduced in TLX1-positive T-ALL samples when compared to
TAL1-positive samples. Interestingly, TLX1 is a genetic subtype
associated with steroid resistance (supplemental Figure 7F).44,45
Although reduced ESRRB expression was observed in paired
ALL samples at the time of relapse and in GC-resistant ALL
samples (supplemental Figure 7A,D,F), we confirmed that the
ESRRB protein was detected in GC-resistant (50% inhibitory
concentration .1 mM) primary T-ALL patient samples (supple-
mental Figure 7G), thereby validating ESRRB as a potential
therapeutic target for GC resensitization in relapsed ALL. Finally,
we demonstrated that dexamethasone significantly increased
ESRRB mRNA levels in the human T-ALL cell line KOPTK1 and
in 2 relapsed T-ALL patient samples examined (supplemental
Figure 7A,H). Consistent with these data, dexamethasone
increased GR binding to the human ESRRB gene in a T-ALL
patient sample (supplemental Figure 7I).39 Collectively, these
data suggest that ESRRB expression is induced by dexameth-
asone to feedback and potentiate GR activity and that ESRRB
suppression results in GC resistance.
Although ERRs have no known endogenous ligands, synthetic
phenolic acyl hydrazones increase the activity of these receptors by
stabilizing the AF-2 domain and increasing coactivator recuitment.46
ESRRB and ESRRG agonists suppress gastric cancer and breast
cancer growth in vitro.47,48 Initially, we tested the effects of the
ESRRB/G agonist DY131 on GC responses in human T-ALL cell
lines. We detected significant increases in dexamethasone-induced
apoptosis and gene expression when dexamethasone and the
ESRRB/G agonist DY131 were used in combination (Figure 7A-B).
The combination therapy resulted in significant decreases in the
viability of 5 T-ALL patient samples examined, including 2 samples
from patients with relapsed leukemia (TLX-14 and -13) who were
resistant to dexamethasone (Figure 7C). We also examined the
effects of a second ESRRB agonist GSK4716 and found similar
increases in apoptotic leukemic cells after combination treatment
(Figure 7D). We evaluated agonist selectivity in mouse T-ALL cells,
where treatment with agonist alone induced cell death (Figure 7E).
GSK4716, and to a lesser extent DY131, induced cell death that was
dependent on the expression of ESRRB (Figure 7E). The combined
effect of GSK4716 and dexamethasone was evaluated by the
combination index (CI) method in 2 human T-ALL cell lines: KOPTK1
and DND-41. This analysis resulted in a CI , 1, indicating that
GSK4716 and dexamethasone synergized to induce leukemic cell
death (Figure 7F), providing proof of principle that ESRRB activation
potentiates dexamethasone-induced cell death in human T-ALL cells.
Discussion
Despite increases in overall survival, relapse remains a critical
challenge in the care of pediatric patients with ALL. Although
failure to respond to GCs can predict a patient’s outcome,3,4 GC
resensitizing agents have not entered the clinic. Our functional
screen for GC-resistance genes identified ESRRB as a dexameth-
asone-inducible transcription factor that cooperates with the GR to
maximize the GC-regulated gene expression signature. We provide
evidence that ESRRB directly contributes to dexamethasone-
induced gene expression in human T-ALL cells through direct
binding to ERREs in the regulatory regions of the GR target
genes examined.
It is likely that ESRRB cooperates with the GR to regulate gene
expression through DNA binding, followed by coactivator re-
cruitment in leukemic cells, similar to findings in ES cells where
ESRRB interacts with NCOA3 to mediate gene transcription.49 The
coactivator(s) that function with ESRRB remain unclear; however,
EP300, NCOA4, and NCOA5 were identified in this screening
(supplemental Table 3), suggesting that they may collaborate with
ESRRB in leukemic cells. Through transcriptome analyses, we
established that ESRRB and GR had overlapping gene regulatory
functions in theGC response in leukemic cells. However, only 66% of
the dexamethasone-induced genes depended on ESRRB (Figure 2),
indicating that other transcription factors remain to be discovered
that coregulate GR transcriptional activity in lymphoid cells.
Figure 7. (continued) dexamethasone1DY131 for 72 hours, and apoptosis was assayed by annexin V-FITC/7-AAD staining followed by flow cytometry. Dexamethasone and
DY131 dual treatment increase dexamethasone-induced gene expression in the human T-ALL cell line KOPTK1 in vitro. (B) Cells were treated with vehicle, dexamethasone
(1 mM), DY131 (10 mM), or dexamethasone1DY131 for 24 hours, and NR3C1, BCL2L11, and TSC23D3 expression was analyzed by qRT-PCR. The copy number was
normalized to b-actin by the DDCT method. T-ALL patient samples are sensitive to dexamethasone and DY131 dual treatment. (C) Cells were treated with vehicle or
dexamethasone (50 nM) and/or DY131 (50 mM), and cell viability was assayed by CellTiterGlo. Treatment with dexamethasone and GSK4716 increased GC-induced
apoptosis in human ALL cells in vitro. (D) Human ALL cell lines were treated with vehicle (DMSO), dexamethasone (1 mM), GSK4716 (10 mM), or dexamethasone1GSK4716
for 72 hours, and apoptosis was assayed by annexin V-FITC/7-AAD staining followed by flow cytometry. The ESRRB agonists GSK4716 and DY131 require ESRRB to induce
leukemic cell death. (E) NS or ESRRB-deficient mouse T-ALL cells were treated with DY131 or GSK4716 (10 mM) for 48 hours, and apoptosis was assayed by annexin
V-FITC/7-AAD staining followed by flow cytometry. GSK4716 synergized with dexamethasone to induce human leukemic cell death. The human T-ALL cell lines KOPTK1 and
DND-41 were treated with increasing doses of GSK4716 and dexamethasone, and cell viability was determined by CellTiterGlo. (F) The CI was calculated by using the formula
a/A 1 b/B. Synergisms, additive effect, and antagonism of combined treatment assays were defined as CI , 1, CI 5 1, and CI . 1, respectively. The results are averages of 3
independent experiments; error bars represent SEM. *P , .05; **P , .01; ***P , .001.
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ESRRB functions as a pioneer factor in the reprogramming of
epiblast stem cells, leading us to speculate that ESRRB may
increase chromatin accessibility at select GR target genes.50 Our
Hi-ChIP analysis of GR- and ESRRB-dependent genes showed that
enhancer elements known to bind the GR in human T-ALL cells39
contain ESRRB binding sites and that dexamethasone increases
the frequency of these enhancer/promoter interactions (Figure 4).
These data lead us to speculate that ESRRB and GR potentiate
GC-induced gene expression by supporting these chromatin
interactions. Our Hi-ChIP data also detected preexisting chromatin
interactions at dexamethasone-responsive loci in mouse and
human T-ALL cells (Figures 3 and 4), indicating that lymphoid cells
may be poised for a rapid transcriptional GC response.
Our work establishes ESRRB repression as a mechanism of GC
resistance and relapse in ALL. Treatment of human T- or B-ALL cell
lines and samples with the ESRRB agonists DY131 or GSK4716
enhanced dexamethasone-induced gene expression and cell death.
These in vitro data led us to administer DY131 in vivo to assess its
effects on leukemic burden. The solubility resulting from the
hydrophobic nature of the agonist51prevented assessment of its
cooperating/synergizing with dexamethasone to prevent leukemic
growth in vivo. Future collaborative efforts will be directed at
improving agonist pharmacokinetics.
This work reveals novel functions of ESRRB as a GR regulator. We
showed that ESRRB is a GC-responsive gene and is coenriched,
along with GR at select GC-regulated target genes in human ALL
cells. Our study provides mechanistic insight into GR transcription
and establishes ESRRB as a potential therapeutic target to enhanceGC
action in acute leukemia and potentially other lymphoid malignancies.
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